1. Academic Validation
  2. Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis

Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis

  • J Med Chem. 2016 Apr 28;59(8):3808-25. doi: 10.1021/acs.jmedchem.5b02004.
Aaron T Garrison 1 Yasmeen Abouelhassan 1 Verrill M Norwood 4th 1 Dimitris Kallifidas 1 Fang Bai 1 Minh Thu Nguyen 1 Melanie Rolfe 1 Gena M Burch 1 Shouguang Jin 1 Hendrik Luesch 1 Robert W Huigens 3rd 1
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, College of Pharmacy, ‡Department of Molecular Genetics & Microbiology, College of Medicine, and ⊥Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida , Gainesville, Florida 32610.
Abstract

Persistent bacteria, including persister cells within surface-attached biofilms and slow-growing pathogens lead to chronic infections that are tolerant to Antibiotics. Here, we describe the structure-activity relationships of a series of halogenated phenazines (HP) inspired by 2-bromo-1-hydroxyphenazine 1. Using multiple synthetic pathways, we probed diverse substitutions of the HP scaffold in the 2-, 4-, 7-, and 8-positions, providing critical information regarding their Antibacterial and Bacterial eradication profiles. Halogenated phenazine 14 proved to be the most potent biofilm-eradicating agent (≥99.9% persister cell killing) against MRSA (MBEC < 10 μM), MRSE (MBEC = 2.35 μM), and VRE (MBEC = 0.20 μM) biofilms while 11 and 12 demonstrated excellent Antibacterial activity against M. tuberculosis (MIC = 3.13 μM). Unlike antimicrobial peptide mimics that eradicate biofilms through the general lysing of membranes, HPs do not lyse red blood cells. HPs are promising agents that effectively target persistent bacteria while demonstrating negligible toxicity against mammalian cells.

Figures